JERSEY CITY, N.J., Aug. 29, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in the following upcoming investor conferences:
About SCYNEXISSCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
CONTACT:
Investor RelationsNatalie WildenradtArgot PartnersTel: [email protected]
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: [email protected]
Advertisement
- Baird's 2018 Global Healthcare Conference at the InterContinental New York Barclay Hotel on Wednesday, September 5, 2018 at 2:00 p.m. ET.
- The H.C. Wainwright 20th Annual Global Investment Conference at the St. Regis New York on Thursday, September 6, 2018 at 12:30 p.m. ET.
- The Oppenheimer Fall Summit at the Langham, New York, Fifth Avenue on Wednesday, September 26, 2018.
Advertisement
About SCYNEXISSCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
CONTACT:
Investor RelationsNatalie WildenradtArgot PartnersTel: [email protected]
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: [email protected]
View original content:http://www.prnewswire.com/news-releases/scynexis-inc-to-participate-in-upcoming-investor-conferences-300701931.html
SOURCE SCYNEXIS, Inc.
